The responses of 14 hyperlipidemic subjects to 4 hypolipidemic agents were compared by measureing cholesterol and triglyceride in whole plasma, very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) monthly for 2 months before and 3 months during treatment with each of 4 drugs: clofibrate, 2 g/d; colestipol, 20 g/d; para-aminosalicylic acid-ascorbate (PAS-C), 6–8 g/d; and oxandrolone, 7.5 mg/d. Lipid responses proved to be stable by the first monthly evaluation both off and on each drug. Mean adherence was high and similar for all agents (81–92% of the prescribed dose). Clofibrate was associated with significant decreases in mean plasma cholesterol (−16%, p<.01), plasma triglyceride (−51%, p<.005), VLDL-cholesterol (−61%, p<.005) and VLDL-triglyceride (−61%, P<.005), while HDL cholesterol increased (+20%, p<.01), and the LDL-cholesterol/HDL ratio declined (−24%, p<.05). Colestipol was associated with decreases in mean plasma cholesterol (−15%, p<.01) and LDL-cholesterol (−22%, p<.05), while VLDL-triglyceride increased (+41%, p<.05), and the LDL-cholesterol/HDL-cholesterol ratio declined (−25%, p<.05). PAS-C was associated with decreases in VLDL-cholesterol (−30%, p<.05), and VLDL-triglyceride (−29%, p<.05), while the LDL-cholesterol/HDL-cholesterol ratio remained unchanged. Oxandrolone was associated with increases in mean plasma cholesterol (+7%, p<.05), LDL-cholesterol (+45%, p<.005 [+25% excluding one subject who increased 298%]), and LDL-triglyceride (+24%, p<.01), while decreases occurred in plasma triglyceride (−31%, p<.05), VLDL-cholesterol (−26%, p<.05), VLDL-triglyceride (−42%, p<.005), HDL-cholesterol (−45%, p<.005), and HDL-triglyceride (−43%, p<.01). The mean LDL-cholesterol/HDL-cholesterol ratio increased by 109% (p<.005), reflecting the reciprocal changes in LDL and HDL. Thus, while both clofibrate and colestipol were associated with significant, equivalent reductions in theoretical atherogenic risk, oxandrolone produced a net effect that was not only adverse but 4 times that magnitude, suggesting caution in its long-term use, even for the management of hypertriglyceridemia.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Cheung, M.C., Albers, J.J., Wahl, P.W., and Hazzard, W.R. (1980) Atherosclerosis 35, 215–228.
Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., and Dawber, T.R. (1977) Am. J. Med. 62, 707–714.
Brunzell, J.D., Schrott, H.G., Motulsky, A.G., and Bierman, E.L. (1976) Metabolism 25, 313–320.
Noble, R.P. (1968) J. Lipid Res. 9, 693–700.
Fredrickson, D.S., Morganroth, J., and Levy, R.I. (1975) Ann. Int. Med. 82, 150–157.
Warnick, G.R., Mayfield, C., Albers J.J., and Hazzard, W.R. (1979) Clin. Chem. 25, 279–284.
Lipid Research Clinics Program Manual of Laboratory Operations, (1974) Vol. 1, Lipid and Lipoprotein Analysis, Washington, D.C., US Government Printing Office, DHEW Pub No 75-628.
Winer, B.J. (1962) in Statistical Principles in Experimental Design, McGraw-Hill Book Company, New York, Chapter 7.
Marascuilo, L.A., and McSweeney, M. (1977) in Nonparametric and Distribution-free Methods for the Social Sciences, pp. 176, Brooks/Cole Publishing Co.
Grundy, S.M. (1982) Med. Clin. N. Am. 66, 519–535.
Kane, J.P., and Malloy, M.J. (1982) Med. Clin. N. Am. 66, 537–550.
Albers, J.J., Cheung, M.C., and Hazzard, W.R. (1978) Metab. Clin. Exp. 27, 479.
Breslow, J.L., Spaulding, D.R., Lux, S.E., Levy, R.I., and Less, R.S. (1975) New Eng. J. Med. 293, 900–903.
Goldstein, J.L., Dana, S.E., Brunschede, G.Y., and Brown, M.S. (1975) Proc. Natl. Acad. Sci. U.S.A. 72, 1092–1096.
Brown, M.S., Kovanen, P.T., and Goldstein, J.L. (1981) Science 212, 628–635.
Utermann, G., Vogelberg, K.H., Steinmetz, A., Schoenborn, W., Pruin, N., Jaeschke, M., Hees, M., and Canzler, H. (1979) Clin. Genet. 15, 37–62.
Zannis, V.I., Just, P.W., and Breslow, J.L. (1981) Am. J. Hum. Genet. 3, 11–24.
Havel, R.J. (1982) Med. Clin. N. Am. 66, 441–454.
Hazzard, W.R., Warnick, G.R., Utermann, G., and Albers, J.J. (1981) Metabolism 30, 79–88.
Hazzard, W.R., Albers, J.J., Baron, P., Miller, N., Warnick, G.R., and Lewis, B. (1981) Lancet 1, 298–301.
Wilson, D.E., and Lees, R.S. (1972) J. Clin. Invest. 51, 1051–1057.
Goldstein, J.L., Hazzard, W.R., Schrott, H.G., Bierman, E.L., and Motulsky, A.G. (1973) J. Clin. Invest. 52, 1544–1568.
Boman, H., Hazzard, W.R., Albers, J.J., Cooper, M.N., and Motulsky, A.G. (1975) Am. J. Human Genet. 27, 19A.
Oliver, M.R., Heady, J.A., Morris, J.N., and Cooper, J. (1978) Br. Heart J. 40, 1069–1179.
Lippel, K., Tyroler, H., Eder, H., Gotto, Jr., A., and Vahouny, G. (1981) Arteriosclerosis 1, 406–417.
Brunzell, J.D., and Bierman, E.L. (1982) Med. Clin, N. Am. 66, 455–468.
William R. Hazzard was an investigator of the Howard Hughes Medical Institute during the course of this study
Claude Gagne was a research fellow of the Medical Research Council of Canada during the course of this study.
John J. Albers is an established investigator of the American Heart Association. of this study
About this article
Cite this article
Hazzard, W.R., Wahl, P.W., Gagne, C. et al. Plasma and lipoprotein lipid responses to four hypolipid drugs. Lipids 19, 73–79 (1984). https://doi.org/10.1007/BF02534494
- High Density Lipoprotein
- Lipid Research Clinic